Model‐based simulation to support the approval of isatuximab alone or with dexamethasone for the treatment of relapsed/refractory multiple myeloma in Japanese patients

• Κύριοι συγγραφείς: Hoai‐Thu Thai (Συγγραφέας), Kimiko Koiwai (Συγγραφέας), Yoshihisa Shitara (Συγγραφέας), Hirotaka Kazama (Συγγραφέας), Jean‐Baptiste Fau (Συγγραφέας), Dorothée Semiond (Συγγραφέας), Christine Veyrat‐Follet (Συγγραφέας)
• Μορφή: Βιβλίο
• Έκδοση: Wiley, 2023-12-01T00:00:00Z.
• Θέματα: article
• Διαθέσιμο Online: Connect to this object online.

Abstract This study aimed to support dosing regimen selection for isatuximab as a single agent or in combination with dexamethasone for Japanese patients with relapsed/refractory multiple myeloma (RRMM). A joint model characterizing the dynamics of serum M‐protein kinetics and its association with p...